Vitality Watch

Dossier pubmed preclinical 25-sep-2026
Animal model, organoid, or cell-culture result — not yet human

Type 2 Angiotensin II receptor (AT2R) deficiency exacerbates cardiac senescence and fibrosis in aging mice.

Key claim: AT2R knockout in aging mice worsens cardiac systolic/diastolic function, fibrosis, senescence (p53/p21), SASP and NLRP3-inflammasome signaling, causes early DNA damage, and shortens median lifespan by about five months versus wild-type.

Abstract

Cardiac aging increases susceptibility to cardiovascular diseases. Cellular senescence may be involved in the development of age-related cardiac diseases. Extensive evidence derived from both clinical and experimental studies suggest that the Type 2 Angiotensin II receptor (AT2R) exerts a potent cardioprotective effect, however, its potential contribution to age-related cardiac complications remains unknown. In this study we used AT2R knockout (AT2-KO) and wild-type mice (WT) both aged (18-21-month-old) and young (4-5-month-old) and evaluated the repercussions cardiac of aging. Old AT2-KO mice exhibited impaired systolic and diastolic cardiac function and exacerbated fibrosis accompanied by increased fibrotic markers expression. The absence of AT2R accelerated the cardiac senescence process in old mice, evidenced by early increase in p53 and p21. In addition, aged AT2-KO mice showed increased expression of Senescence-Associated Secretory Phenotype (SASP) components, activation of cardiac NF-kB and NLRP3-inflammasome followed by increased levels of cardiac IL-1β and IL-18 compared to aged WT mice. AT2R deficiency also resulted in significant DNA damage even in young animals and it was associated with a 5-month reduction in median lifespan (26 months for AT2R-KO vs. 31 months for WT). These findings suggest potential mechanisms whereby AT2R acts as a key mediator of cardiac senescence and cardioprotection during aging.

Why this matters

AT2R has historically been treated as a bit-player opposite AT1R in the renin–angiotensin system, invoked mostly for its cardioprotective signaling. This mouse knockout study nominates AT2R as an active brake on cardiac senescence, fibrosis, and NLRP3-inflammasome activity whose loss shortens lifespan — connecting a well-drugged pathway (RAS) to core mechanistic aging biology. No human evidence exists, and the AT1R-blocker clinical apparatus does not translate directly to AT2R agonism.

Source

Link

Briefing card

Type 2 Angiotensin II receptor (AT2R) deficiency exacerbates cardiac senescence and fibrosis in aging mice.
Stage: preclinical · pubmed · 25-sep-2026

Applies to preclinical RAS-and-aging research; no change for anyone currently on ARBs or ACE inhibitors, since AT2R agonists are not clinically available.

AT2R knockout in aging mice worsens cardiac systolic/diastolic function, fibrosis, senescence (p53/p21), SASP and NLRP3-inflammasome signaling, causes early DNA damage, and shortens median lifespan by about five months versus wild-type.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1042/CS20261713

build build 880 · 2bcef25 · 2026-11-18